Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 2/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | MC3R | P41968 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28960724 | 0.83 | GABRP (0.36) | MEN1ALDH1A1GAAMAPTMAPK1 | |
| SCHEMBL14854851 | 0.72 | ALDH1A1 (0.34) | ALDH1A1GAAMAPT | |
| SCHEMBL12970650 | 0.72 | NNMT (0.41) | NNMTPDPK1SMN1; SMN2GDAMEN1 | |
| SCHEMBL28419373 | 0.71 | GAA (0.46) | PDPK1MEN1ALDH1A1GAAMAPT | |
| SCHEMBL28546020 | 0.70 | HPGD (0.45) | SMN1; SMN2MEN1ALDH1A1GAAMAPT | |
| SCHEMBL1684235 | 0.70 | LCK (0.36) | NNMTSMN1; SMN2ALDH1A1MAPTMAPK1 | |
| SCHEMBL14983663 | 0.68 | POLB (0.40) | NNMTMAPK1SIRT6IKBKB | |
| SCHEMBL7064548 | 0.68 | POLB (0.40) | NNMTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL339177 | 0.67 | — | — | |
| SCHEMBL29382162 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | claimed |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | ASTELLAS PHARMA INC. (JP) | 2005-12-08 | — | — | US | claimed |
| EP-1518855-A1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-03-30 | — | — | EP | claimed |
| EP-3134439-B1 | ANTI-PSYK ANTIBODY MOLECULES AND USE OF SAME FOR SYK-TARGETED THERAPY | MILLENNIUM PHARM INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20180066068-A9 | ANTI-PSYK ANTIBODY MOLECULES AND USE OF SAME FOR SYK-TARGETED THERAPY | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-08 | — | — | US | disclosed |
| EP-2917186-B1 | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFN | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-3134439-A1 | ANTI-PSYK ANTIBODY MOLECULES AND USE OF SAME FOR SYK-TARGETED THERAPY | Millennium Pharmaceuticals, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170037151-A1 | ANTI-PSYK ANTIBODY MOLECULES AND USE OF SAME FOR SYK-TARGETED THERAPY | MILLENNIUM PHARM INC (US) | 2017-02-09 | — | — | US | disclosed |
| EP-2321283-B1 | 2,6-DIAMINO-PYRIMIDIN-5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARM INC (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015164330-A1 | ANTI-PSYK ANTIBODY MOLECULES AND USE OF SAME FOR SYK-TARGETED THERAPY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| JP-2010174027-A | DIAMINOPYRIMIDINE CARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC | 2010-08-12 | — | — | JP | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | ASTELLAS PHARMA INC. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1518855-A1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | NNMT 397/4885PDPK1 1241/4885SMN1; SMN2 4649/4885 |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | STAT5A, STAT6, STAT4 | NNMT 155/4885PDPK1 755/4885SMN1; SMN2 4496/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | NNMT 397/4885PDPK1 1241/4885SMN1; SMN2 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.